352 related articles for article (PubMed ID: 29259189)
21. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
22. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
23. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
25. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.
Findlay S; Nair R; Merrill RA; Kaiser Z; Cajelot A; Aryanpour Z; Heath J; St-Louis C; Papadopoli D; Topisirovic I; St-Pierre J; Sebag M; Kesarwala AH; Hulea L; Taylor EB; Shanmugam M; Orthwein A
Blood Adv; 2023 Jul; 7(14):3485-3500. PubMed ID: 36920785
[TBL] [Abstract][Full Text] [Related]
26. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
[TBL] [Abstract][Full Text] [Related]
28. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
29. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
30. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
31. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.
Wang Q; Lin Z; Wang Z; Ye L; Xian M; Xiao L; Su P; Bi E; Huang YH; Qian J; Liu L; Ma X; Yang M; Xiong W; Zu Y; Pingali SR; Xu B; Yi Q
Blood; 2022 Jan; 139(1):59-72. PubMed ID: 34411225
[TBL] [Abstract][Full Text] [Related]
32. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.
Soriano GP; Besse L; Li N; Kraus M; Besse A; Meeuwenoord N; Bader J; Everts B; den Dulk H; Overkleeft HS; Florea BI; Driessen C
Leukemia; 2016 Nov; 30(11):2198-2207. PubMed ID: 27118406
[TBL] [Abstract][Full Text] [Related]
34. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
36. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
37. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
38. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
39. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
40. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
